Introduction
The spiro[pyrrolidine-oxindole] system is an attractive object for synthesis because of their important biological properties. Spirooxindole structures can be found in a wide range of complex natural products [1] [2] [3] [4] [5] [6] ; besides many synthetically obtained compounds with this core demonstrate anti-nicotinic, antiplasmodial, antimicrobial, anti-HIV, antimalarials and anti-tumor activities [7] . Different spiro[pyrrolidine-oxindole] display considerable anticancer action that is apparently related to their ability to inhibit p53-MDM2 protein−protein interaction [8] [9] [10] [11] [12] [13] . Some of them were tested as anticancer drugs during preclinical or clinical studies [14] [15] [16] [17] . The most active spiro[oxindole] derivatives inhibit the p53-MDM2 interaction with the IC50 values of 24.1 nM -81 μM [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . At the same time, substantially less studied dispiro-derivatives of pyrrolidine-oxindole have IC50 values in the range of 0.001 -0.05 μM [18] . Thus, the introduction of additional spiro-junction into the system can lead to an increase in antitumor activity.
One of the most effective strategy for the synthesis of dispiro[pyrrolidine-oxindole] is 1,3dipolar cycloaddition of azomethine ylides to electron-deficient alkenes as dipolarophiles.
Basing on them, an effective one-pot access to polynuclear dispiroheterocyclic structures, containing indolinone and pyrrolodine fragments, has been suggested [19] [20] [21] [22] [23] [24] . Recently we proposed regioselective synthesis of 2-thioxo-5H-dispiro[imidazolidine-4,3-pyrrolidine-2,3indole]-2,5(1H)-diones which have been identified as potent small molecule MDM2/p53 PPI inhibitors [12] . These compounds have in the structure thiohydantoin fragment, spiroannelated to the pyrrolidine cycle. It is known that thiohydantoin derivatives are widely used in drug design as core structures. Several thiohydantoins exhibited a variety of biological activities including antiviral and antitumor activities [25] [26] [27] ; for example Enzalutamide (Xtandi) is used in the treatment of prostate cancer.
It is also known numerous applications in medicinal chemistry and drug development of adamantane derivatives (see, for example, [28] [29] [30] . The adamantane modifications usually allows to enhance lipophilicity and stability of the drugs. Lipophilic nature of adamantane allows to modify known pharmacophores, thus enhancing their stability and pharmacokinetics [9] . Introduction of adamantyl group allows not only the creation of effective drugs, but also helps in understanding of the ongoing molecular mechanisms. For example, M2 ion-channels of type A influenza virus were studied with its inhibition by aminoadamantane [33] [34] [35] . Enzyme inhibition is another rapidly developing area of application for adamantane derivatives. The most important among them are DPP-IV inhibitors and antidiabetic drugs -Vildagliptin and Saxagliptin [36] . Other examples of enzyme targets for adamantane-based pharmaceuticals are soluble epoxide hydrolases [37] [38] [39] , protein phosphatase 2A [40] , or the hydroxysteroid dehydrogenases [41] . Adamantane derivatives are being investigated as anti-cancer agents.
For example, cisplatin analog LA-12 ([(OC-6-43)-bis(acetato)(1-adamantylamine)-amminedichloroplatinum(IV)] containing bulky hydrophobic 1-adamantylamine, shows high cytotoxicity against cisplatin-resistant ovarian adenocarcinoma [42] , prostate cancer [43] , colorectal cancer [44] . High potency of this compound related with adamantane derived enhanced cell uptake [45] . Study of Lavendustin C analogs showed that change of methyl substituent in tyrphostin AG 957 with adamantyl led to 12-fold increase of its half-life in vivo [46] .
It may be expected that dispiroindolinones with a rigid lipophilic adamantane fragment will better fit into a small but deep hydrophobic pocket in MDM2, which is apparently the most important site for binding with p53 or the inhibitor molecule [47] and thus contribute to more effective inhibition of the p53-MDM2 interaction.
Therefore, coupling of three privileged scaffolds (spiro[pyrrolidine-oxindole], 2thiohydantoin and adamantane moieties) would open access to the compounds with a wide spectrum of physiological activity, including anticancer one. Based on this, in this work we set out to develop a synthetic approaches to dispiro[pyrrolidine-oxindoles], combining in the structure the above structural fragments.
Results and Discussion
Recently, we have demonstrated that the reaction of 3-aryl-5-arylidene-substituted thiohydantoins with isatine and sarcosine leads to the formation of the dispiro-indolinone derivatives with good regio-and diastereoselectivity [12] . Herein, we present a one-pot reaction of 3-adamantylmethyl-5-methylene-substituted thiohydantoin with two types of azomethine ylides, forming from N-substituted -amino acids and formaldehyde or Nsubstituted -amino acids and isatins.
We started our research by preparation of initial adamantly-substituted electron-deficient alkenes 3 and 5 for 1,3-dipolar cycloaddition of azomethine ylides starting from methyl-(2adamantyl)isothiocyanate 1 [48] , and commercially available glicine, substituted benzaldehydes and isatines 4a-c (Scheme 1). At the first step, 3-adamantylmethyl-substituted thiohydantoin 2 was synthesized by the nucleophilic addition reaction of glycine amino group at the electrophilic carbon atom of the isothiocyanate group of compound 1; the thiourea formed in this way was not isolated from the reaction mixture, but was cyclized to thiohydantoin under the addition of HCl. Then, thiohydantoin 2 was introduced into the condensation reaction with benzaldehydes or isatins to obtain the target dipolarophiles 3 and 5.
The yields of the obtaining compounds 3-5 are given in Table 1 .
Compounds 3a-c are formed as single geometric isomers, which is confirmed by the presence of the only vinyl proton signal in their 1 H NMR spectra at 6.55-6.70 ppm. The Z configuration was attributed to products 3 basing on the chemical shifts of the vinylic protons in the 1 H NMR spectra [48] . The configuration of the isatins condensation products 5 was attributed basing on X-ray data for the reaction product of compound 5b with azomethylilide (dispiroindolinone 7b, see Figure 1 , right). Scheme 1. Synthesis of starting dipolarophiles 3 and 5. For synthesis of target dispiropyridine 6 and 7, the reactions of azomethine ylides generated from isatin and sarcosine or from formaldehyde and N-substituted aminoacids to dipolarophiles 3 and 5 were used which allowed to vary the position of the pyrrolidine nitrogen atom relative to the place of spiro-junction with oxindole fragment. The reactions provided the desired compounds 6a-i, 7a-f in a moderate-to-high yield (See Tables 2, 3 ). 
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The conversion proceeded regioselectively providing pure diastereometric products with The formation of compounds 7 obviously proceeds according to a similar mechanism with the initial formation of azomethinilide D (Scheme 3). Spiro-cyclization with the participation of dipolarophiles 5 in this case is accompanied by the formation of two new stereo centers, and in practice also proceeds with the isolation of the only diastereomers of products 7 with the relative (4R*,4`R*)-configuration in high yield (see Table 2 ). colleagues [49] . The detailed methodology describing the performed cell-based evaluation is provided in Supplenentary Information. The resulting cytotoxicity is summarized in Table 4 below. All synthesized compounds demonstrated higher or the same in vitro cytotoxicity against the tested cell lines compared with Nutlin-3a and cisplatin. The most cytotoxic compounds was dispiro-oxindoles 7a and 7b. [51, 52] .
In an effort to elucidate the underlying mechanism of action of the synthesized compounds as p53/MDM2 interaction inhibitors, we have performed cell based assay with the p53 reporter construction particularly sensitive to MDM2 inhibitors. To assess the level of p53 protein accumulation, the test system of A549 tumor cells modified with a plasmid construct containing p53-recognized regions regulating β-galactosidase expression was used. This approach suggests that with an increase in the amount of p53 protein during the experiment, the content of β-galactosidase increases, which, when using the ONPG indicator (onitrophenyl-β-galactoside) releases a colored compound into the medium [50] . Four dilutions of compounds 6, 7 (100 to 1.56 μM) were tested. The tests results are presented in Table 5 .
Nutlin-3a, a known inhibitor of p53/MDM2 interaction, which was used as a positive control, causes direct activation of p53 via the block of p53-MDM2 interaction and elevates p53 activity from 3.6 up to 5.1-fold in the reporter assay [52] In general, the obtained results demonstrated that the activation of p53 was observed upon the treatment with high concentrations of the compounds 6, 7. The maximum activation was observed for compounds 6i and 7a; the treatment of cells by these compounds in 100 µM concentration leads to the 2.03 and 4.39 times p53 activation. For the most synthesized compounds the activation of p53 is less than for Nutlin-3a at the same conditions, but comparable with indirect cisplatin action, which suggests that the investigated compounds have indirect p53-dependent mechanism of cytotoxic action. Only for compound 7a in high concentration (> 100 µM) the mechanism of cytotoxic activity associated with the inhibition of the p53/MDM2 interaction can be supposed. conditions, Nutlin-3a showed from 5.1-and up to 8-fold increase in the p53 activation [51, 52] .
Conclusions
In the present study, two series of novel adamantane-substituted dispiro[pyrrolidine-oxindole] derivatives has been described based on a regio-and diastereoselective 1,3-dipolar cycloaddition of azomethine ylides to electron-deficient alkene systems. Synthesized dispirooxindoles demonstrated high in vitro cytotoxicity with different cancer cell lines, and, apparently, in most cases have indirect p53-dependent mechanism of cytotoxic action.
Experimental Section
General Information. All common reagents were purchased from commercial suppliers and used as received. The melting points are uncorrected. 1 H and 13 C NMR spectra were recorded on a Bruker Avance spectrometer (400 MHz for 1 H, 100 MHz for 13 C) in DMSO-d 6 . Chemical shifts are reported in parts per million relative to TMS. High resolution mass spectra (HRMS)
were recorded on an Orbitrap Elite (Thermo Scientific) mass spectrometer with an IRET. To inject solutions with a concentration of 0.1 to 9 μg / ml (in 1% formic acid in acetonitrile), direct injection into the ion source using a syringe pump (5 μl/min) was used. The spray voltage was ± 3.5 kV, the temperature of the capillary was 275ºC. Methyl-(2-adamantyl)isothiocyanate 1 was prepared using previously described procedures [53, 54] .
3-(adamantan-1-ylmethyl)-2-thioxoimidazolidin-4-one (2).
Glycine (1 eq.) was dissolved in a pyridine-water mixture (5:1). Then triethylamine (1.1 eq.) and isothiocyanate 1 (1.1 eq.) were added. The resulting mixture was heated to 55 °C and stirred at this temperature for 2 hours.
Pyridine and the excess of isothiocyanate were removed by extraction with toluene and the organic phase was discarded. Aqueous phase was neutralized by concentrated hydrochloric acid to pH 6-7 and boiled for 2.5 hours. The reaction mixture was evaporated under reduced pressure to half of the volume and cooled to room temperature. The formed precipitate was filtered off and recrystallized from methanol. Yield 72%. The product is grey crystalline solid. General Procedure for the Synthesis of Compounds 3.. Compound 2 (1 eq.) was dissolved in 2% KOH/EtOH and then substituted benzaldehyde (1 eq.) was added. The resulting mixture was stirred for 3 h; after the reaction was completed, the mixture was neutralized with 1N HCl.
The formed precipitate was filtered off, washed with water, than cold ether and dried in air.
The products are yellow crystalline solids.
(Z)-3-(adamantan-1-ylmethyl)-5-(2-chlorobenzylidene)-2-thioxoimidazolidin-4-one (3a).
Compound 2 (0.175 g, 0.66 mmol) was dissolved in 2% KOH/EtOH (5 mL) and 2chlorobenzaldehyde (0.093 g, 0.66 mmol) was added. The resulting mixture was stirred for 3 h; after the reaction was completed, the mixture was neutralized with 1N HCl (5 mL). The formed precipitate was filtered off, washed with water (5 mL), than cold ether (5 mL) and dried in air, yielding 3a (0.189 g, 74% General Procedure for the Synthesis of Compounds 5. Compound 2 (1 eq.) was dissolved in 1% KOH/EtOH and then isatin derivative 4a-c (1 eq.) was added. The resulting mixture was stirred for 0,5 h. After the reaction was completed, the mixture was neutralized with 1N HCl.
(Z)-3-(adamantan-1-ylmethyl)-5-(3-chlorobenzylidene)-2-thioxoimidazolidin-4-one (3b).
The products are red crystalline solids. General Procedure for the Synthesis of Compounds 6. The mixture of 5-(benzylidene)-2thioxoimidazolidines 3 (1 equiv) and sarcosine (2 eq.) were brought to a boil in ethanol. After that isatin 4a-c (2 eq.) was added. The resulting mixture was refluxed for 5-8 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, the formed precipitate was filtered off, washed with cold ethanol and dried in air. The products are white crystalline solids. added. The resulting mixture was refluxed for 5-8 hours. After the reaction was completed, the solvent was evaporated in vacuo. The product was then purified using column chromatography (silica gel 60, 0.04-0.063 mm/ 230-400 mesh, CHCl3:MeOH/50:1) to afford yellow or pink solid. This solid was washed with small amount of methanol to yield corresponding dispirooxindole as white crystalline solid.
